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Edited by Lukas HuberAbstract We investigated whether HER2 downregulation by
trastuzumab modulates the responsiveness of breast cancer cells
to TNF-related apoptosis-inducing ligand (TRAIL). Interest-
ingly, in contrast to increased response to TRAIL in SKBr3
cells, trastuzumab decreased the susceptibility of BT474 cells
to TRAIL. This decrease was also observed after exogenous
inhibition of PI3-K/Akt kinase, but not MAPK/ERK kinase
(MEK)/mitogen-activated protein kinase (MAPK). In BT474
cells, but not SKBr3 cells, inhibition of the HER2/phosphatidyl-
inositol 30 kinase (PI3K)/Akt pathway resulted in downregulation
of the pro-apoptotic receptors TRAIL-receptor 1 (TRAIL-R1)
and TRAIL-R2. TRAIL-induced caspase-8 activation, Bid pro-
cessing, drop of DWm, and poly ADP-ribose polymerase (PARP)
cleavage but not in caspase-9 activation, and these events were
inhibited in HER2/PI3K/Akt-suppressed BT474 cells, which on
the other hand exhibited downregulation of Bcl-xL and increased
response to mitomycin C. We show that HER2/PI3K/Akt path-
way may play a speciﬁc pro-apoptotic role in certain cell type by
inducing TRAIL-R1 and -R2 expression and thereby enhancing
responsiveness to TRAIL.
 2005 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Aberrations in the apoptotic signaling promote tumorigenesis
and underlie resistance of human tumors to anticancer agents.
At the cell surface, signals for cell death can be transmitted
through TNFR1, CD95/Fas, TNF-related apoptosis-inducing
ligand-receptor 1 (TRAIL-R1)/DR4 and TRAIL-R2/DR5
which are members of the tumor necrosis factor (TNF) receptor
family known as death receptors. Apoptosis via TRAIL-R1 and
TRAIL-R2 is induced by their interaction with TRAIL, a deathAbbreviations: TNF, tumor necrosis factor; TRAIL, TNF-related
apoptosis-inducing ligand; TRAIL-R, TRAIL-receptor; MAPK, mito-
gen-activated protein kinase; MEK, MAPK/ERK kinase; PI3K, ph-
osphatidylinositol 3 0 kinase; FLIP, Flice-inhibitory protein; IAP,
inhibitor of apoptosis protein; DWm, mitochondrial membrane poten-
tial; PARP, poly ADP-ribose polymerase
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doi:10.1016/j.febslet.2005.06.047ligand that is interesting for cancer therapy for several reasons.
First, unlike other members of the TNF ligand family, TRAIL
preferentially induces apoptosis in transformed cells, whereas it
is relatively benign to normal cells [1]. Second, the TRAIL eﬀec-
tor pathway appears a physiological component of the immuno-
surveillance of tumor cells by natural killer and T cells [2–5].
Binding of TRAIL to its receptors TRAIL-R1 and TRAIL-
R2 triggers formation of a death-inducing signaling complex
(DISC) leading to activation/self-processing of proximal pro-
caspase-8 and -10 [6]. Subsequently, in type I cells, the apopto-
tic cascade might proceed, in a mitochondria-independent
manner, directly to the processing of eﬀector caspases and
downstream apoptotic events; or alternatively, in type II cells,
it involves insertion of caspase-8-processed Bid into the mito-
chondrial membrane followed by release of apoptogenic mole-
cules and the activation of eﬀector caspases. Thus, starting at
the cell membrane, TRAIL-induced cell death can be
modulated at any of these several stages. The transcriptional
activities of p53 [7] and NF-jB [8,9] are mostly responsible
for regulating the surface levels of TRAIL-R1 and TRAIL-
R2, and are frequently modulated in cancer cells. Furthermore,
susceptibility to TRAILmight be negatively regulated by abun-
dant expression of the decoy receptors TRAIL-R3 and TRAIL-
R4 [10,11]. At the DISC, a high level of a competitive caspase-8
inhibitor Flice-inhibitory protein (FLIP)L/S has been shown to
diminish TRAIL-induced apoptosis [12]. As apoptotic signal-
ing from TRAIL-Rs often requires mitochondria-mediated
ampliﬁcation, a high level of mitochondrial anti-apoptotic
Bcl-2 family proteins, such as Bcl-2 and Bcl-xL, can suppress
TRAIL-induced apoptosis. Similarly, overexpression of inhib-
itor of apoptosis protein (IAP) family proteins that inhibit cas-
pase activity, particularly XIAP and survivin negatively
regulates responsiveness to TRAIL [13]. Likewise, resistance
to TRAIL has been correlated with impeded release of mito-
chondrial Smac/DIABLO [14] and Omi/HtrA2 [15], proteins
that promote caspase activity by inhibiting the IAP proteins.
In various cancer types including breast carcinomas, overex-
pression of the HER2 (neu/ErbB-2) receptor tyrosine kinase, a
member of the ErbB (epidermal growth factor receptor) fam-
ily, underlies enhancement in proliferative, prosurvival and
metastatic signaling [16,17]. Thus, patients with HER2-over-
expressing carcinomas exhibit poor clinical outcome, exempli-
ﬁed by a lower overall survival rate and shorter time to relapse,
compared to those with HER2 negative tumors [18,19].
The humanized anti-HER2 antibody trastuzumab
(Herceptin) was developed to abrogate the growth ofation of European Biochemical Societies.
4150 L. Dubska´ et al. / FEBS Letters 579 (2005) 4149–4158HER2-overexpressing cancer cells [20,21]. To date, trastuzumab
has been approved for use in the treatment of metastatic breast
cancer when combined with chemotherapy [22,23] and as a sin-
gle agent in the ﬁrst-line therapy of HER2-overexpressing ad-
vanced breast cancer [24,25]. Nevertheless, HER2 expression
levels might only partially determine the therapeutic eﬃcacy
of trastuzumab; in clinical settings of trastuzumabmonotherapy
of metastatic breast cancer, close to two-thirds of patients with
HER2 overexpression do not experience tumor regression, and
the majority of patients initially responding to this drug subse-
quently develop resistance [26]. Although the biological eﬀects
of trastuzumab alone or its combination with chemotherapy
are not completely understood, both extracellular and intracel-
lular mechanisms seem to play a role in the antitumor activity of
trastuzumab. In vitro studies demonstrated that the major part
of antitumor action of trastuzumab results fromupregulation of
cyclin-dependent kinase inhibitor p27Kip1 and subsequent cell
cycle arrest in breast cancer cell lines [27–29]. However, in pri-
mary breast tumors [30] and in a model of cellular-dependent
cytotoxicity of glioblastoma cell lines [31], trastuzumab has been
shown to increase apoptosis rate but not cell cycle inhibition. In
the whole-body context, binding of trastuzumab on the surface
of Her-2-overexpressing cell stimulates NK cell-mediated anti-
body-dependent cellular cytotoxicity [32–34] and complement-
dependent toxicity [35]. Nevertheless, both pro-apoptotic and
antiproliferative actions of trastuzumab on the intracellular le-
vel are attributed to inhibition of transforming signals down-
stream of HER2, including constitutively activated Raf/MEK/
mitogen-activated protein kinase (MAPK) and phosphatidylin-
ositol 3 0 kinase (PI3K)/Akt kinase pathways [32,36]. Particu-
larly, the prosurvival activity of PI3K/Akt has been frequently
described resulting from regulation of number of proteins in-
volved in the cell cycle, apoptosis, protein synthesis and glyco-
gen metabolism [37], including p27Kip1 [28] and Bad whose
Akt-mediated phosphorylation on Ser136 prevents its pro-
apoptotic action on the mitochondrial membrane [38].
Here, we investigated whether HER2-overexpressing breast
carcinoma cells responded to trastuzumab by enhanced suscep-
tibility to TRAIL which was reported for other cell lines [39].
Finding unexpected suppressive eﬀect of trastuzumab on
TRAIL-induced apoptosis in BT474 cells, we further analyzed
signaling pathways downstream of the HER2 receptor and
apoptosis-related proteins and events regulated by trastuzumab.2. Materials and methods
2.1. Cell culture and treatment
Breast adenocarcinoma-derived cell lines were cultured in medium
supplemented with 10% fetal bovine serum (Gibco, NY, USA), gluta-
mine, and antibiotics (Sigma, St. Louis, MO, USA) at 37 C in 5%
CO2; speciﬁcally BT474 and MCF-7 cells in Dulbeccos modiﬁed
Eagles medium (Sigma) and SKBr-3 cells in McCoys medium (Sig-
ma). In experiments determining the eﬀect of pretreatments on
TRAIL-induced apoptosis, subconﬂuent cultures were incubated with
trastuzumab (Herceptin Genentech, CA, USA), LY-294002 (Alexis,
Switzerland), or PD-98059 (Calbiochem, CA, USA). Apoptosis was in-
duced by addition of human recombinant TRAIL, prepared as in [40],
at a ﬁnal concentration of 20 ng/ml.
2.2. Apoptotic features
Cells were examined for apoptotic morphology using phase-contrast
microscopy and photographed. Apoptotic cells exhibiting fragmenta-
tion of intracellular cytokeratin-18 were analyzed using the M30 Cyto-death assay (Roche Diagnostics, Germany). Brieﬂy, cells were
trypsinized, washed in Hanks balanced salt solution (HBSS) contain-
ing 0.1% Tween 20 (HBSS-Tween), ﬁxed for 30 min in pure methanol
at 20 C, washed twice in HBSS-Tween, and incubated for 1 h at
room temperature in the dark with ﬂuorescein isothiocyanate (FITC)-
conjugated M30 antibody diluted 1:250 in HBSS-Tween containing
1% bovine serum albumin (BSA). After two washes in HBSS-Tween,
the percentage of M30-positive cells was analyzed on Epics XL ﬂow
cytometer (Coulter, FL, USA) using the manufacturers analysis soft-
ware. For DNA content analysis, ﬂoating cells were pooled together
with trypsinized adherent cells, washed twice with HBSS, and incubated
for at least 4 h at 4 C in DNA staining solution [50 lg/ml propidium
iodide (PI), 10 mM Tris, 0.1% TRITON X-100, 0.07% RNase, 0.1%
sodium chloride] and analyzed by ﬂow cytometry. The percentage of
sub-G1 gated signals reﬂects the proportion of apoptotic cells.
Changes in mitochondrial membrane potential (DWm) were assessed
according to accumulation of tetramethylrhodamine ethyl ester
(TMRE; Molecular Probes, OR, USA) in the negatively charged mito-
chondrial matrix of intact living cells. Cells were incubated with
400 nM TMRE for the last 30 min in the cell culture medium at
37 C. Then, attached cells were harvested by trypsinization, washed
once in PBS (phosphate buﬀered saline) supplemented with 100 nM
TMRE (PBS–TMRE), and pooled with ﬂoating cells. Cells were resus-
pended in 1 ml of PBS–TMRE, stained with PI at a ﬁnal concentration
of 0.5 lg/ml and analyzed by ﬂow cytometry. Dead cells were excluded
according to their high PI ﬂuorescence (FL-3 channel). TMRE ﬂuores-
cence was measured at 575 nm (FL-2 channel).
Expression of mitochondrial apoptosis-related protein 7A6 was de-
tected using PECy5-conjugated Apo2.7 mAb (Immunotech, France).
Adherent cells were trypsinized, pooled with ﬂoating cells, washed
once in PBS containing 0.2% BSA (PBS-BSA) and permeabilized by
incubation with 100 ll of 100 lg/ml digitonin (Sigma) solution for
20 min on ice. Cells were washed in PBS-BSA and stained with 10 ll
of either Apo2.7-PECy5 Ab or PECy5 isotype control for 15 min at
room temperature. After one wash in PBS-BSA, Apo2.7 staining was
detected at 675 nm using ﬂow cytometry.2.3. Immunoﬂuorescent staining
The cell surface expression of HER2 receptor was measured as the
amount of selective binding sites for trastuzumab, a humanized anti-
body containing the murine antigen binding loops and human variable
region framework residues plus human IgG1 constant domains [41], fol-
lowed by secondary staining with an antibody reacting speciﬁcally with
the Fc portion of the heavy chain of human IgG1 (Molecular Probes).
First, breast cancer cells were trypsinized and washed twice with ice-
cold HBSS containing 0.2% BSA (HBSS-BSA). Resuspended cells were
incubated with trastuzumab for 30 min at 4 C. Next, cells were washed
twice, incubated with Alexa Fluor 488-conjugated mouse anti-human
IgG1 secondary mAb, washed twice in HBSS-BSA, stained with PI at a
ﬁnal concentration 0.5 lg/ml and analyzed. Dead cells and debris were
excluded according to their increased PI ﬂuorescence and forward scat-
ter properties. Alexa Fluor 488-conjugated mouse anti-human IgG1
mAb alone was used as an isotype-matched control.
To determine surface expression of TRAIL-Rs, adherent cells were
trypsinized and washed twice with ice-cold HBSS-BSA. Resuspended
cells were incubated with FITC-conjugated anti-human TRAIL-R1
(clone HS101), anti-human TRAIL-R2 (clone HS201) mAbs (Alexis),
or FITC-IgG1 isotype control Ab (Immunotech, ME, USA) for 1 h at
4 C, washed twice, stained with PI and analyzed as described above.
To determine the expression of intracellular proteins, adherent cells
were harvested by trypsinization, washed in PBS, and ﬁxed by resus-
pending in PBS containing 0.4% formaldehyde for 10 min at 37 C.
After washing, cells were permeabilized by incubation with pure meth-
anol for 30 min at 20 C. After one wash in PBS-BSA, cells were
stained according to the manufacturers recommendations with
FITC-conjugated anti-human Bcl-xL mAb (Chemicon, CA, USA) or
with FITC-conjugated anti-human Bcl-2 mAb (DAKO A/S, Den-
mark) and with isotype-matched Abs, washed twice in PBS-BSA and
analyzed by ﬂow cytometry.2.4. Western blot
Whole-cell lysates were separated by SDS–PAGE gels and trans-
ferred onto nitrocellulose membranes (BioRad, CA, USA). The
membranes were blocked with 5% non-fat milk in PBS containing
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of the following primary antibodies: rabbit anti-p44/42 MAPK,
anti-Akt, anti-phospho-Akt (Ser473), anti-phospho-Bad (Ser136)
(Cell Signaling Technology, MA, USA), anti-cIAP-1, anti-cIAP-2,
anti-XIAP (R&D Systems, MN, USA), anti-FLIP (Alexis Biochemi-
cals, Switzerland), and anti-caspase-9 (Apotech, Switzerland); mouse
anti-phospho-p44/42 MAPK (Thr202/Tyr204) (Cell Signaling Tech-
nology), anti-caspase-8 (Alexis Biochemicals), anti-poly ADP-ribose
polymerase (PARP) (Calbiochem), anti-caspase-3 (Apotech), anti-
p27 (F-8) (SantaCruz Biotechnology, CA, USA), and anti-actin (Sig-
ma); goat anti-Bid (c-20) (SantaCruz Biotechnology). After three
washes, membranes were probed with appropriate horseradish perox-
idase-conjugated swine anti-rabbit, rabbit anti-mouse (DAKO A/S),
or rabbit anti-goat (SantaCruz Biotechnology) secondary antibodies
according to the manufacturers instructions. Immunoblots were
visualized by an enhanced chemiluminescence (ECL) kit (Amersham
Biosciences).3. Results
3.1. Suppression of TRAIL-induced apoptosis by trastuzumab in
HER2 positive breast cancer cells
We evaluated the role of HER2 expression and its suppres-
sion by trastuzumab on the susceptibility of MCF-7 and
BT474 breast carcinoma cells to apoptosis induced by TRAIL.
Surface expression of HER2 was low on MCF-7 cells andFig. 1. Diﬀerential modulation of responsiveness to TRAIL-induced apo
adenocarcinoma cell lines, MCF-7 (a–d) and BT474 (e–h), were stained for H
induced apoptosis in the presence or absence of trastuzumab (b–d, f–h). (a, e)
HER2 Ab trastuzumab, followed by secondary anti-human IgG1Ab (dark line
mean ﬂuorescence intensity index (MFI index) was calculated as (MFI of c
stained with anti-human IgG1Ab alone) and is shown in each histogram. (b–d
(40 lg/ml) for 48 h. All cultures were exposed to the sensitizing agent cyclohex
added to speciﬁed dishes. (b, f) After an additional 24 h, cells were harvested
after TRAIL administration, DNA content analysis was performed. (b, c, f, g
(means ± S.D.). Statistical signiﬁcances of diﬀerences in apoptosis between the
determined by Students t test. *P < 0.05; ns, not signiﬁcant. (d, h) Represenrelatively high on BT474 cells (Fig. 1(a) and (e)). In MCF-7
cells, treatment with trastuzumab had no eﬀect on caspase-
dependent fragmentation of cytokeratin 18 (CK18) or generation
of sub-G1 events (Fig. 1(b) and (c)). Combination of trast-
uzumab with TRAIL also had no eﬀect on TRAIL-induced
apoptosis (Fig. 1(b)–(d)). In contrast, BT474 cells responded
to trastuzumab with an observable increase in both CK18 frag-
mentation and generation of sub-G1 events. Furthermore, 48 h
pretreatment with trastuzumab substantially suppressed
TRAIL-induced apoptosis in BT474 cells (Fig. 1(f)–(h)). The
sensitizing agent cycloheximide was used in these experiments
because treatment of both breast cancer cell lines with TRAIL
alone at concentrations as high as 200 ng/ml, resulted in a sig-
niﬁcant, however, less easily measurable apoptotic response
(data not shown). In summary, unlike the HER2-low-express-
ing MCF-7 cells, treatment with trastuzumab in HER2-over-
expressing BT474 cells directly induced apoptosis but
reduced apoptosis induced by TRAIL.
3.2. Trastuzumab-mediated suppression of Akt and MAP
kinases diﬀerentially aﬀect TRAIL-induced apoptosis
PI3K/Akt kinase and MAPK/ERK kinase (MEK)/MAPK
are two major components of the signaling pathways that
transmit mitogenic and survival signals from the HER2ptosis in breast cancer cells treated with trastuzumab. Two breast
ER2 expression (a, e) and examined for their susceptibility to TRAIL-
Membrane HER2 expression was determined by staining with the anti-
), compared to staining with anti-human IgG1Ab alone (light line). The
ells stained with trastuzumab and anti-human IgG1Ab)/(MFI of cells
, f–h) Cells were maintained in the presence or absence of trastuzumab
imide (CHX; 2 lg/ml) for an additional 4 h and TRAIL (20 ng/ml) was
and analyzed for cleavage of cytokeratin 18 (CK18). (c, g) Forty hours
) Representative results from three independent experiments are shown
groups with trastuzumab pretreatment and without pretreatment were
tative photomicrographs of each culture are shown.
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tion on speciﬁc serine and threonine residues [44,45]. We ana-
lyzed the dose eﬀect of trastuzumab on TRAIL-induced
apoptosis and on activation of these kinases in HER2 positive
trastuzumab-responsive BT474 cells. Increasing concentra-
tions of trastuzumab induced a rapid decrease in susceptibility
to TRAIL and a signiﬁcant reduction in phosphorylation of
both Akt and p44/42 MAP kinases (Fig. 2(a) and (b)). The
reduction in responsiveness to TRAIL reached a plateau at
10 lg/ml (Fig. 2(a)) of trastuzumab, a concentration that was
reported to be the minimum that was eﬀective for the antican-
cer eﬀect of trastuzumab [21]. In the following experiments,
trastuzumab was used at 40 lg/ml, as a concentration achiev-
able in serum in clinical settings [46].
Next, we examined whether direct inhibition of PI3K/Akt or
MEK/MAPK signaling mimicked trastuzumab by inducing a
similar reduction in susceptibility to TRAIL. Suppression of
MEK/MAPK signaling with the MEK1 inhibitor PD-98059,
in the subtoxic concentration 20 lM, modestly but signiﬁ-
cantly sensitized BT474 cells to TRAIL-induced apoptosis.
In contrast, treatment of BT474 cells with PI3K inhibitor
LY-294002 resulted in virtually complete inhibition of
TRAIL-induced cell death (Fig. 2(c)). This demonstrated the
involvement of the PI3K/Akt kinase pathway, a downstream
component of the HER2 signaling pathway, in downregula-
tion of responsiveness to TRAIL.
3.3. Trastuzumab and PI3K/Akt kinase inhibition aﬀect the
expression of apoptosis-related proteins
Trastuzumab- and LY-294002-mediated suppression of
TRAIL-induced apoptosis prompted us to analyze whether
both agents exert similar eﬀects on the expression of proteinsFig. 2. Inhibition of PI3K/Akt kinase and MAPK exerts diﬀerential eﬀects o
cancer cells. (a, b) BT474 cells were grown in the presence of the speciﬁed co
CHX and TRAIL as in Fig. 1. After 40 h, apoptosis was assessed as the perce
of trastuzumab on the activities of MAPK and Akt kinase, total protein extr
for 48 h were immunoblotted with anti-phospho-p44/42 MAPK (Thr202/Tyr
Blotting with anti-p44/42 MAPK and anti-Akt Abs is shown as a loading co
MAPK kinase pathway, or LY-294002 (20 lM), an inhibitor of the PI3K/Ak
and apoptosis was measured as in (a). (a, c) The means ± S.D. of triplicates fr
induced apoptosis (Students t test).participating in TRAIL-induced apoptotic pathway. After a
48 h incubation with trastuzumab, BT474 cells exhibited
downregulation of both pro-apoptotic surface receptors for
TRAIL (TRAIL-R1 and -2; Fig. 3(a)). Trastuzumab caused
a slight decrease in Bcl-xL expression but did not aﬀect Bcl-2
expression. Similarly, cell treatment with LY-294002 led to
an almost complete suppression of the surface expression of
both TRAIL-Rs and also to strong downregulation of Bcl-xL
expression (Fig. 3(a)). Immunoblot analysis of the anti-apop-
totic proteins FLIPL, FLIPS, IAP-1, IAP-2, and XIAP in trast-
uzumab- and LY-294002-treated cells revealed no signiﬁcant
diﬀerence in the expression of FLIPL/S protein and IAP family
proteins (Fig. 3(b)). We observed slight decrease of the level of
mitochondrial protein Bad phosphorylated on Ser136 after
LY-294002 which was undetectable in trastuzumab-treated
cells. Furthermore, both trastuzumab and LY-294002 caused
an increase in p27Kip1 protein. The signiﬁcant changes in pro-
tein levels, namely downregulation of TRAIL-R1, TRAIL-R2,
and Bcl-xL and upregulation of p27
Kip1, were by induced by
both trastuzumab and LY-294002 which is consistent with
the notion that trastuzumab aﬀects TRAIL susceptibility by
modulating the PI3K/Akt kinase pathway.
3.4. Diﬀerential eﬀect of trastuzumab and PI3K/Akt kinase
inhibition on TRAIL- versus mitomycin C-induced cell
death
Trastuzumab- or LY-294002-mediated inhibition of the
expression of Bcl-xL expression (Fig. 3(a)) suggested that
downregulation of HER2 and/or PI3K/Akt kinase signaling
might have sensitized BT474 cells to apoptosis induced via
the mitochondrial pathway. Mitomycin C is a DNA-crosslink-
ing agent capable of inducing death receptor-independentn the susceptibility to TRAIL in trastuzumab-responsive BT474 breast
ncentrations of trastuzumab for 48 h. (a) All cultures were treated with
ntage of cells exhibiting sub-G1 DNA-content. (b) To examine the eﬀect
acts from cells treated with the speciﬁed concentrations of trastuzumab
204) Ab (upper panel) and anti-phospho-Akt (Ser473) Ab (lower panel).
ntrol. (c) Cells were incubated with PD-98059 (20 lM), an inhibitor of
t kinase pathway. After 48 h, cells were treated with TRAIL (20 ng/ml)
om a representative experiment are shown. (c) *P < 0.05 from TRAIL-
Fig. 3. Expression of proteins involved in the TRAIL-induced apoptotic pathway. BT474 cells were grown in the presence or absence of trastuzumab
(40 lg/ml) or LY-294002 (20 lM) for 48 h followed by CHX (2 lg/ml) for an additional 4 h. (a) Surface expression of TRAIL-R1 and TRAIL-R2
was determined in viable, intact cells (left panel). The level of intracellular Bcl-xL and Bcl-2 was assessed in permeabilized cells (right panel). Dark
lines represent staining of the indicated proteins with FITC-conjugated mAbs; light lines represent IgG1 isotype control labeling. MFI index,
calculated as in Fig. 1, is given in each histogram. (b) Cell lysates were prepared and immunoblotted with Abs against FLIP, IAP-1, IAP-2, XIAP,
phospho-Bad, p27Kip1 or actin (as a loading control).
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cules. We compared the eﬀect of trastuzumab and LY-294002
on TRAIL- and mitomycin C-induced cell death in BT474 cells
(Fig. 4(a) and (b)). Whereas preincubation of BT474 cells with
trastuzumab produced a substantial decrease in susceptibility
to TRAIL it enhanced cell death induced by mitomycin C.
Similarly, inhibition of PI3K/Akt kinase signaling resulted in
virtually complete reduction in responsiveness to TRAIL and
in enhancement of mitomycin C cytotoxicity. Thus, the apop-
tosis-inhibiting eﬀect of trastuzumab and PI3K/Akt kinase
suppression is speciﬁc to the TRAIL pathway and does not
apply to DNA damage-induced cell death.
3.5. Eﬀects of trastuzumab and PI3K/Akt kinase inhibition on
the components of TRAIL-induced apoptotic pathway
We proceeded to analyze the eﬀects of pretreatments with
trastuzumab and LY-294002 on downstream components of
the TRAIL-induced apoptotic signaling pathway (Fig. 5).
We observed that TRAIL alone induced a signiﬁcant reduc-
tion in the number of cells with high DWm. Although both
trastuzumab and LY-294002 decreased the fraction of livingcells with high DWm, pretreatment with trastuzumab signiﬁ-
cantly diminished the TRAIL-induced drop in DWm and
LY-294002 completely abrogated it (Fig. 5(a)). In cells
stained by Apo2.7 antibody for apoptosis-related mitochon-
drial membrane protein, we observed the analogous, how-
ever, not thus profound trend (Fig. 5(b)). Apoptosis
induction by TRAIL resulted in processing of procaspase-8
(54/55 kDa) to its intermediate forms (41 and 43 kDa) and
its active form (18 kDa); cleavage of full-length Bid protein
(23 kDa) to its truncated form (15 kDa); processing of pro-
caspase-3 (32 kDa) to its catalytic subunits (17 and
12 kDa); and cleavage of PARP (116 kDa) to yield its 85-
kDa inactive fragment (Fig. 5(c)). Pretreatment with trast-
uzumab partially inhibited TRAIL-induced caspase-8 and
caspase-3 processing, Bid and PARP cleavage, and LY-
294002 pretreatment almost fully inhibited the processing
(Fig. 5(c)). The procaspase-9 (46 kDa) was not processed to
its cleavage products (37 and 35 kDa) in any treatment group
(Fig. 5(c)). These data indicate that the observed protection
of BT474 cells from TRAIL-induced apoptosis occurs up-
stream of mitochondria.
Fig. 4. Diﬀerential eﬀects of inhibition of Her-2 signaling and PI3-K/
Akt kinase on TRAIL- and mitomycin C-induced apoptosis. BT474
cells were grown in the presence or absence of trastuzumab (40 lg/ml)
or LY-294002 (20 lM) for 48 h. (a) Apoptosis induction by TRAIL
was performed as in Fig. 1. (b) After 48 h of pretreatment with
inhibitors, speciﬁed cultures were exposed to mitomycin C (4 lg/ml).
(a, b) Following an additional 48 h, cells were harvested for DNA
content analysis. Data are representative of four independent exper-
iments. The percentage of cells with sub-G1 DNA content is shown in
each histogram.
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induced apoptosis and expression of receptors for TRAIL
Because our ﬁndings were not in line with the general view of
pro-apoptotic eﬀect of trastuzumab and suppression of PI3K/
Akt kinase and especially with the data on trastuzumab-med-
iated enhancement of TRAIL-induced apoptosis [39], we
investigated the eﬀect trastuzumab on susceptibility of other
HER2-overexpressing cell lines (Fig. 6(a)) to TRAIL. SKBr3
cells were pretreated with the concentration of trastuzumab
up to 160 lg/ml exceeding the serum concentration of the anti-
body [46], however, 160 lg/ml corresponds to 1 lM trast-
uzumab which was used as a pretreatment in [39]. Here, we
shown that trastuzumab (40 and 160 lg/ml) signiﬁcantly in-
creased TRAIL-induced apoptosis which is in agreement with
data published by Cuello et al. Moreover, compared to BT474
cells (Fig. 3(a)) we observed slight upregulation of both
TRAIL-R1 and TRAIL-2 after trastuzumab in SKBr3 cells
(Fig. 6(c)). Thus, two investigated HER2-overexpressing cell
lines diﬀer signiﬁcantly in eﬀect of trastuzumab on expression
of TRAIL-R1 and TRAIL-R2 and on responsiveness to
TRAIL corresponding to level of these receptors.4. Discussion
Trastuzumab was developed to suppress the growth of
HER2-overexpressing malignant cells while sparing normal
HER2-low cells. Thus, as expected, we found that eﬀect of
trastuzumab was restricted to HER2-high BT474 and SRBr3
cells. In these two cell lines, but not in HER2-low MCF-7
cells, treatment with trastuzumab resulted in growth inhibi-
tion (data not shown) but not in signiﬁcant amount of apop-
tosis, and in modulation of TRAIL-induced apoptosis. HER2
receptor signaling has been reported to confer resistance to
apoptosis induced by various stimuli, including genotoxic
agents such as cisplatin [47], paclitaxel [48], doxorubicin
[49], etoposide [50], and radiation [51], as well as ligation of
death receptors by TNF [52] and TRAIL [39]. In agreement
with these ﬁnding, we demonstrated trastuzumab-induced in-
crease in sensitivity to mitomycin C in BT474 cells and to
TRAIL in SKBr3 cells. Nevertheless, we observed signiﬁcant
reduction of TRAIL-induced apoptosis in trastuzumab-pre-
treated BT474 cells.
Examining this unexpected eﬀect on the susceptibility to
TRAIL in BT474 cells, we found that the main HER2 down-
stream pathways, Raf/MEK/MAPK and PI3K/Akt kinase
[42,43], were inhibited by trastuzumab, but that MAPK and
Akt kinase signaling diﬀered in their regulation of TRAIL-
responsiveness. In agreement with a prosurvival action of
MAPK [53,54], we observed modest but signiﬁcant enhance-
ment of susceptibility to TRAIL following MEK/MAPK inhi-
bition. However, contrary to reports indicating a protective
eﬀect of Akt kinase signaling on TRAIL-induced apoptosis
in other cell lines [55–58] we found that PI3K/Akt kinase sig-
naling is required for responsiveness of BT474 breast cancer
cells to TRAIL. Taken together, MEK/MAPK and PI3K/
Akt kinase pathways exert an opposing eﬀect on TRAIL-
responsiveness downstream of HER2 – where the PI3K/Akt
kinase pathway predominated – resulting in an overall reduc-
tion in susceptibility to TRAIL-induced apoptosis after trast-
uzumab treatment.
Focusing further on HER2/PI3K/Akt kinase signaling, its
inhibition by trastuzumab or LY-294002 resulted in a decrease
of Bcl-xL protein expression and a proportional increase in
sensitivity to mitomycin C-induced cell death. These observa-
tions are in agreement with previous reports that Bcl-xL is
downstream of HER2/PI3K/Akt kinase signaling and that
downregulation of this mitochondrial protein is responsible
for the pro-apoptotic response caused by suppression of
HER2 and Akt kinase [55,58]. This sensitization of breast car-
cinoma cells to mitomycin C-induced apoptosis following
downregulation of HER2 signaling or suppression of the
PI3K/Akt kinase pathway provides additional support for
therapeutic strategies that exploit the enhanced responsiveness
of HER2-overexpressing cells to genotoxic drugs after trast-
uzumab treatment [59,60] by extending the repertoire of che-
motherapeutics to mitomycin C.
As mentioned above, suppression of the HER2/PI3K/Akt
signaling pathway resulted in reduced susceptibility to
TRAIL, which was observable at numerous stages of the
apoptotic cascade, including suppression of TRAIL-induced
processing of apical caspase-8, mitochondrial protein Bid
and caspase-3, and drop of DWm. However, mitochondrial
membrane potential was reduced also in trastuzumab-treated
and PI3K/Akt-supressed cells, which on one hand corre-
Fig. 5. The eﬀect of trastuzumab and LY-294002 pretreatment on downstream events in the TRAIL-induced apoptotic pathway. Cells were treated
as in Fig. 4(a). (a) Fourteen hours following TRAIL-treatment, cells were collected and mitochondrial membrane potential was measured with
TMRE dye. Data points demonstrate the percentage of cells with speciﬁc TMRE retention, calculated as [(% of viable cells with high TMRE in each
treatment group)/(% of untreated cells with high TMRE)] * 100. The means ± S.D. of triplicates from a representative experiment are shown. The
statistical signiﬁcance of diﬀerences between groups was determined by Students t test. *P < 0.05 from the group without pretreatment; P < 0.01;
P < 0.02; ns, not signiﬁcant. (b) Eighteen hours after treatment with TRAIL, staining with Apo2.7 Ab was detected. In each contour plot, the
percentage of PECy5 positive cells is given, gates were set according to PECy5-conjugated isotype control. (c) Twelve hours after exposure to
TRAIL, whole cell lysates were prepared and immunoblotted with Abs against caspase-8, Bid, PARP, caspase-9, caspase-3 and actin.
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partial dephosphorylation of phospho-Bad, but on the other
hand does not reﬂect the terminal apoptotic events and the
rate of cell death. The ﬁnding that drop of DWm, is not suf-
ﬁcient for apoptosis together with the relatively low mito-
chondrial apoptosis-speciﬁc staining with Apo2.7 and the
inability of TRAIL to induce processing of procaspase-9 de-
spite of pre-mitochondrial apoptogenic events including gen-
eration of truncated Bid, suggests that at least partial
resistance of BT474 cells to apoptosis is mitochondria-re-
lated. This is consistent with low rate of cell death in
high-dose mitomycin C-treated cells. Moreover, facts that
TRAIL caused activation of caspase-3 without processing
of procaspase-9 and that responsiveness to TRAIL is not de-
creased by caspase-9 inhibitor (Z-LEHD-FMK) in BT474
cells (data not shown) implied that TRAIL-induced apopto-
sis is caspase-9-independent. This conclusion further ex-
plained the observation that susceptibility to TRAIL in
HER2/PI3K/Akt kinase-suppressed BT474 cells is not in-
creased by existing downregulation of Bcl-xL and stronglysuggest that TRAIL-induced apoptosis is not dependent on
the mitochondria-related pathway and is substantially regu-
lated by the expression of TRAIL-Rs and post-receptor
events in BT474.
It has been reported that membrane expression of death
receptors crucially regulates the death receptor-mediated
apoptosis [60,61]. In both investigated HER2-overexpressing
cell lines, we observed modulation of expression of TRAIL-
R1 and TRAIL-R2, which was consistent with response to
TRAIL in respective cells. Supporting our previous assump-
tion that TRAIL-induced apoptosis is receptor-dependent in
BT474 cells, we found that suppression of HER2/PI3K/Akt ki-
nase leading to downregulation of TRAIL-Rs may protect
BT474 cells from TRAIL-induced killing. Considering the dif-
ferential role of trastuzumab in responsiveness to TRAIL in
two investigated HER2-overepressing cell lines along with
the previously demonstrated data [39,57,58], we concluded that
the protective eﬀect of trastuzumab and suppression of PI3K/
Akt on TRAIL-induced apoptosis is cell-speciﬁc and it may be
relevant for other cell types with similar molecular properties,
Fig. 6. Trastuzumab aﬀects diﬀerentially susceptibility to TRAIL in
HER2-overexpressing SKBr3 cells. (a) Membrane HER2 expression
was assessed as in Fig. 1(a) and (e). (b) SKBr3 cells were treated with
indicated concentrations of trastuzumab for 48. Next, all cultures were
treated with CHX (2 lg/ml) for additional 4 h, and speciﬁed cultures
with TRAIL. After 56 h, apoptosis was assessed as the percentage of
cells exhibiting sub-G1 DNA-content. The means ± S.D. of triplicates
from a representative experiment are shown. The statistical signiﬁcance
of diﬀerences between groups was determined by Students t test.
*P < 0.05, **P < 0.01 from the group without pretreatment. (c) SKBr3
cells were grown in the presence (160 lg/ml) or absence of trastuzumab
for 48 h, treated with CHX (2 lg/ml). Surface expression of TRAIL-
R1 and TRAIL-R2 was measured as in Fig. 3(a).
4156 L. Dubska´ et al. / FEBS Letters 579 (2005) 4149–4158such as an independence of death receptor-mediated apoptosis
on mitochondria-related events.
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